Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics – Sidley Austin

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S.-based law firm also advises China to incorporate international standards for pharmacovigilance and adopt GMPs for APIs, in comments submitted to China’s SFDA.

You may also be interested in...



Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

3SBio, the first Chinese biotechnology company to list on NASDAQ, reported strong second-quarter earnings for its lead EPO and thrombopoietin products and is on track to launch a pre-filled syringe EPO product in China by year-end, the firm announced Aug. 8

Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.

Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter

Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.

Topics

UsernamePublicRestriction

Register

PS066051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel